129 results about "Tryptamine Receptors" patented technology

A compound, as shown in Formula I, is a multi-heterocyclic compound. It has been verified that the compound provided by this invention integrates a novel compound targeting the calcitonin gene-related peptide (CGRP) based on ephedrine. Upon contact with the skin, due to photoactivated cell biological function regulation and the blocking effect of the multi-heterocyclic compound I structure on serotonin receptors, it achieves therapeutic effects on cutaneous vascular malformations and telangiectasia, improves the effectiveness of phototherapy in improving chronic cutaneous vascular diseases, and promotes skin wound healing.

Disclosed herein are methods of treatment and methods of evaluating individuals to identify and measure biomarkers and / or states of the individuals indicative of drug responsiveness to one or more 5-HT receptor agonist.

The disclosure provides methods for the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and for treatment of psychiatric symptoms of viral, bacterial, and autoimmune encephalitis, and for protecting or reinforcing the blood-brain barrier, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A / D2 receptor ligand.

Hallucinogenic and non-hallucinogenic serotonin receptor agonists are disclosed herein in addition to methods of using them for treating and preventing addictions and overdoses.

The present disclosure relates to pharmaceutical compositions formulated with psilocin and / or deuterated psilocin compounds or pharmaceutically acceptable salts, polymorphs, stereoisomers, or solvates thereof, and an organic acid agent as a pharmaceutically acceptable vehicle. Uses in the treatment of diseases, such as those associated, with a 5-HT2 receptor, are also disclosed.

Disclosed herein are salts and solid forms of the benzoselenophene and benzothiophene analogs described herein.

A single unit oral dose pharmaceutical composition for use as a medicament for separate, sequential or simultaneous administration with an agonist of a 5-hydroxytryptamine (5-HT) receptor;wherein the single unit oral dose pharmaceutical composition comprises a first active ingredient and a second active ingredient;wherein the first active ingredient is for absorption in the gastrointestinal tract from the oesophagus onwards and the second active ingredient is for absorption in the oral cavity; andwherein the first active ingredient is naltrexone in an amount of 0.01 to 10 mg and the second active ingredient is calcitriol in an amount of 80 to 200 ug.

The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and / or the μ-opioid receptor.

A method of treating and attenuating L-DOPA-induced dyskinesia, comprising administering an effective dose of at least one pharmacological agent, e.g., vilazodone, having serotonin-specific reuptake inhibition (SSRI) and serotonin receptor 1A (5-HT1AR) partial agonism activity, in conjunction with L-DOPA. Other agents, such as an L-DOPA decarboxylase inhibitor, e.g., carbidopa, or other adjunct treatments may also be provided.

The present invention relates to novel 5HT receptor modulators, such as compounds of general formula (I) and general formula (II) or pharmaceutically acceptable salts thereof. Methods of using the compounds include, for example, modulation of serotonin (5-HT) receptor subtypes, including the serotonin 2A receptor and / or serotonin 2C receptor, and treatment of conditions or diseases wherein the treatment is associated with modulation of serotonin 2A receptor and / or serotonin 2C receptor. # imgabs 0 # formula (I) # imgabs 1 # formula (II).

Pharmaceutical compositions of the invention comprise functionalized lactam derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

The invention discloses a heteroarylamine compound as well as a pharmaceutical composition and application thereof. Specifically, the invention discloses a compound shown as a formula (I) or a pharmaceutically acceptable salt thereof. The compound provided by the invention has one or more of the following advantages: (1) the compound has excellent agonistic activity on a 5-hydroxytryptamine 4 receptor; and (2) the inhibitory activity on hERG is relatively weak.

This disclosure relates, in some embodiments, to substituted ergolines such as 14-monosubstituted and 2,14-disubstituted lysergic amides and their quaternated derivatives. In some embodiments, this disclosure relates to methods for using these compounds, including methods for synthesizing these compounds, compositions containing these compounds, and methods for administering them to subjects. In some embodiments, the characteristics of the compounds include neuromodulatory activity, such as activation of serotonin receptors. In some further embodiments, the compounds are useful as therapeutic agents, such as anti-inflammatory agents. [Formula 1] JPEG2026525309000071.jpg5750

The pharmaceutical composition of the present invention comprises a functionalized lactam derivative having a disease ameliorating effect in the treatment of diseases associated with dysregulation of serotonin receptor 7 activity. # imgabs 0 # A selected from the group consisting of (groups): # imgabs 1 #

This invention belongs to the field of medical technology, and specifically relates to the application of serotonin 3 receptor antagonists in the preparation of antitumor drugs. This invention, through research, demonstrates for the first time that serotonin 3 receptor antagonists can inhibit the activity of tumor cells resistant to third-generation EGFR-TKIs. More importantly, serotonin 3 receptor antagonists can not only reverse HER2 S310F mutation-mediated resistance to third-generation EGFR-TKIs, but also reverse secondary resistance to third-generation EGFR-TKIs, thus enabling their use as antitumor drugs for patients resistant to third-generation EGFR-TKIs. The combined use of serotonin 3 receptor antagonists and third-generation EGFR-TKIs exhibits a significant synergistic effect in inhibiting the proliferation of lung adenocarcinoma cells, with minimal toxic side effects on liver and kidney function, providing an effective treatment strategy for clinically reversing third-generation EGFR-TKI resistance and improving the treatment efficacy of NSCLC.

The present disclosure provides azocino[4,5,6-cd]indoles as serotonin receptor modulators. Uses of said compounds in the treatment of medical disorders, such as neurological or psychiatric disorders, and processes of synthesizing said compounds are also provided.

The present disclosure provides compounds, such as compounds of Formula I, and their use in the treatment of medical diseases or disorders, such as psychiatric and nervous system diseases. Pharmaceutical compositions and methods of making various benzisoxazole and benzisothiazole compounds are provided. These compounds are considered to be modulators of the serotonin 2A (5-HT2A) receptor.

Provided herein are ergoline derivatives which modulate serotonin receptors and compositions thereof. Also provided herein are methods of modulating serotonin receptors and methods of treating diseases and disorders (e.g., pain) in a subject in need thereof. (I)

The present disclosure provides compounds, such as compounds of Formula I, and their use in the treatment of medical diseases or disorders, such as psychiatric and nervous system diseases. Pharmaceutical compositions and methods of making various benzisoxazole and benzisothiazole compounds are provided. These compounds are considered to be modulators of the serotonin 2A (5-HT2A) receptor.

The present disclosure relates to stable pharmaceutical compositions of amorphous psilocybin and deuterated psilocybin, and to the use of such pharmaceutical compositions in the treatment of diseases associated with a serotonin 5-HT2 receptor. The pharmaceutical compositions are formulated with solid dispersions of psilocybin or deuterated psilocybin in amorphous form dispersed in a polymer.

The present invention relates to the technical field of pharmaceuticals and specifically describes an application of a 5-hydroxytryptamine receptor 1A in preparing a drug for portal hypertension. The present invention achieved a significant decrease in portal venous pressure in model rats with cirrhotic portal hypertension by means of an HTR1A inhibitor WAY100635 administered at 1 mg / kg / day by intraperitoneal injection or alverine administered at 15 mg / kg / day by oral gavage. A 5-hydroxytryptamine receptor 1A antagonist can be used to prepare an experimental drug for the treatment of cirrhotic portal hypertension. Furthermore, the 5-hydroxytryptamine receptor 1A antagonist can also be used to prepare drugs for symptoms of portal hypertension syndrome, such as esophageal and fundal varices, rupture and bleeding, ascites, or hepatic encephalopathy. The present invention provides a novel treatment means to treat the manifestations of portal hypertension syndrome, such as esophageal and fundal varices, rupture and bleeding, ascites, or hepatic encephalopathy.

Pharmaceutical compositions of the invention comprise functionalized lactam derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

Hallucinogenic and non-hallucinogenic serotonin receptor agonists are disclosed herein in addition to methods of making and using the same.

The present disclosure provides compounds, such as compounds of Formula I, and their use in the treatment of medical diseases or disorders, such as psychiatric and nervous system disorders. Pharmaceutical compositions and methods of making various tetrahydropyridine and piperidine compounds are provided. The compounds are expected to be modulators of the serotonin 2A (5-HT2A) receptor.

5-HT2A receptor ligands and receptor-ligand complexes are synthesized. These ligands, which may link two indole containing moieties through an amine, may be used in therapeutically effective amounts, to treat mood disorders and neurologic disorders.

Methods and compositions that treat Alzheimer's disease and other neurodegenerative diseases and / or to ameliorate or improve symptoms associated with Alzheimer's disease. In some aspects, the compositions and methods use a serotonin 4 receptor (5-hydroxytryptamine (serotonin) receptor 4, or 5-HT4R) agonist in combination with: (R,S)-ketamine, a (R,S)-ketamine analog, or a pharmaceutically acceptable salt, derivative, or metabolite thereof; an antagonist of the glutamate N-methyl-D-aspartate (NMDA) receptor (NMDAR); or an agonist of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (AMPAR).

Therapeutic combinations for inducing entactogenic states of mind, such as through the use of compositions comprising imidazoline receptor agents, cannabinoid receptor agents, and / or serotonin receptor agents, are disclosed. Also disclosed are certain selective receptor agents, pharmaceutical compositions thereof, and methods of their use for treating mental health conditions, improving mental health and mental function, and designing and creating entactogenic states of mind or mood.

Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

The present disclosure relates to small molecule compound (SMC), pharmaceutical composition comprising the same, uses thereof in methods for treating brain disease.

The present invention describes the combination of a 5HT3-antagonist and / or NK1-antagonist with pramipexole to reduce or eliminate the adverse effects associated with the use of pramipexole and to enable the use of high doses of pramipexole for treating anhedonia.